Vitae Pharmaceuticals (VTAE) Ends 3Q With Cash Available Through 2016; Piper Jaffray Raises Price Target to $18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
November 5, 2015 4:06 PM ESTAnnounces psoriasis as lead indication for VTP-43742
Conference call scheduled for 4:30 p.m. EST today
FORT WASHINGTON, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today reported its operating and financial results for the third quarter ended September 30, 2015.
Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, "During the third quarter of 2015, Vitae continued to make meaningful progress with our lead assets, generating positive... More
